Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 276 posts found.

janssen_latest_logo_on_sign_closer

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016
Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …

News
janssen_latest_logo_on_sign

Genmab receives milestone payment for first Darzalex sale in Europe

May 31, 2016
Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales

Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …

News
janssen_latest_logo_on_sign

Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials

May 26, 2016
Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial

Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials.  The company said a significant …

News

Nice recommends three drugs to treat diabetes

May 25, 2016
Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

News
clinical_trial_3

Darzalex meets endpoint in late-stage multiple myeloma trial

May 19, 2016
Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial

Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …

News
fda2outsideweb

FDA expands Imbruvica label with new survival data

May 11, 2016
Research and Development, Sales and Marketing AbbVie, FDA, Janssen, data, efficacy, expanded, imbruvica, label, late stage, phase III

The US Food and Drug Administration (FDA) has expanded the label of Imbruvica (ibrutinib) to include the data from recent …

News
legal

Janssen and Genmab sued for patent infringement in US

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement

German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).

News
janssen_latest_logo_on_sign_closer

Janssen to stop fulranumab development in osteoarthritis pain

April 1, 2016
Medical Communications, Research and Development, Sales and Marketing Amgen, Janssen

Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain. The J&J company says the decision is …

News
janssen_latest_logo_on_sign

Janssen-Cilag’s HIV treatment gets NHS backing

March 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial

Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV.  The company said following the …

News
cancer_cells

Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours

March 22, 2016
Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour

Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …

News
zytiga

NICE approves Janssen’s Zytiga for prostate cancer before chemo

March 21, 2016
Sales and Marketing Janssen, NICE, Zytiga, prostate cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …

News
janssen_latest_logo_on_sign_closer

Janssen’s Zytiga boosts survival in early-stage prostate cancer

March 14, 2016
Research and Development, Sales and Marketing Janssen, Zytiga, abiraterone, prednisone, prostate cancer

Janssen has announced data from a post-hoc analysis of a Phase III trial showing that Zytiga plus prednisone boosted overall …

News
genmab

Genmab Darzalex success triggers second milestone payment

March 10, 2016
Research and Development, Sales and Marketing Genmab, Janssen, daratumumab, darzalex, follicular lymphoma

Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …

News
abbvie_0

AbbVie’s Imbruvica gets US FDA okay as first-line treatment for CLL

March 7, 2016
Sales and Marketing AbbVie, Janssen, Janssen Biotech, US FDA, imbruvica

Drug maker AbbVie said the US Food and Drug Administration (FDA) has approved its Imbruvica (ibrutinib) as a first-line treatment …

News
janssen_latest_logo_on_sign

Janssen slams NICE decision on Imbruvica

March 2, 2016
Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025